FDA accepts Genentech's pertuzumab BLA and grants Priority Review

[News]

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

More... (http://www.news-medical.net/news/20120208/FDA-accepts-Genentechs-pertuzumab-BLA-and-grants-Priority-Review.aspx)